Phase I/II Study to Determine the Safety and Efficacy of Quercetin in COPD Patients
Latest Information Update: 12 Jul 2023
At a glance
- Drugs Quercetin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Biomarker
- 24 May 2023 Results assessing the efficacy of quercetin in reducing markers of oxidative stress and inflammation in the lung, presented at the 119th International Conference of the American Thoracic Society.
- 24 Jul 2015 Planned End Date changed from 1 Dec 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
- 24 Jul 2015 Planned primary completion date changed from 1 Oct 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov record.